AI Article Synopsis
Article Abstract
Objectives: To report the outcomes of stereotactic ablative body radiotherapy (SABR) in men with oligometastatic prostate cancer (PCa) diagnosed on prostate-specific membrane antigen (PSMA)-positron emission tomography/computed tomography (PET/CT), based on a single-institution experience and the published literature.
Patients And Methods: This was a retrospective cohort study of the first 20 consecutive men with oligometastatic PCa, treated with SABR in a single institution, who had biochemical recurrence after previous curative treatment (surgery/radiotherapy), had no evidence of local recurrence, were not on palliative androgen deprivation therapy (ADT), and had PSMA-PET/CT-confirmed oligometastatic disease (≤3 lesions). These men were treated with SABR to a dose of 30 Gy in three fractions for bone metastases, and 35-40 Gy in five fractions for nodal metastases. The outcomes of interest were: PSA response; local progression-free survival (LPFS); distant progression-free survival (DPFS); and ADT-free survival (ADTFS). A literature review was performed to identify published studies reporting on outcomes of PSMA-PET/CT-guided SABR.
Results: In our institutional cohort, 12 men (60%) had a decline in PSA post-SABR. One man had local progression 9.6 months post-SABR, with 12-month LPFS of 93%. Ten men had distant progression outside of their SABR treatment field, confirmed on PSMA-PET/CT, with 12-month DPFS of 62%, of whom four were treated with palliative ADT, two received prostate bed radiotherapy for prostate bed progression (confirmed on magnetic resonance imaging), and four received a further course of SABR (of whom one had further progression and was treated with palliative ADT). At last follow-up, six men (one with local progression and five with distant progression) had received palliative ADT. The 12-month ADTFS was 70%. Men with longer intervals between local curative treatment and SABR had better DPFS (P = 0.03) and ADTFS (P = 0.005). Four additional studies reporting on PSMA-PET/CT-guided SABR for oligometastatic PCa were identified and included in the review, giving a total of 346 patients. PSA decline was reported in 60-70% of men post-SABR. The 2-year LPFS, DPFS and ADTFS rates were 76-100%, 27-52%, and 58-62%, respectively.
Conclusion: Our results showed that PSMA-PET/CT could have an important role in identifying men with true oligometastatic PCa who would benefit the most from metastases-directed therapy with SABR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bju.14886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of an MRI-Based Radiomics Nomogram to Predict the Prognosis of De Novo Oligometastatic Prostate Cancer Patients.
Cancer Med
December 2024
Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Objective: We aimed to develop and validate a nomogram based on MRI radiomics to predict overall survival (OS) for patients with de novo oligometastatic prostate cancer (PCa).
Methods: A total of 165 patients with de novo oligometastatic PCa were included in the study (training cohort, n = 115; validating cohort, n = 50). Among them, MRI scans were conducted and T2-weighted imaging (T2WI) and apparent diffusion coefficient (ADC) sequences were collected for radiomics features along with their clinicopathological features.
Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients.
Clin Genitourin Cancer
October 2024
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Theodor Stern Kai 7, 60596, Frankfurt, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martini Street 52, 20251, Hamburg, Germany.
Article Synopsis
- Metachronous metastatic prostate cancer (mmPCa) patients exhibit different characteristics and outcomes compared to DeNovo metastatic patients, influenced by primary cancer features like Gleason score (GS) and stage.
- A study of 341 mmPCa patients found that higher Gleason scores and more advanced stages were linked to earlier onset of metastatic disease and significantly affected overall survival (OS) rates.
- The research concluded that longer intervals between initial prostate cancer diagnosis and the onset of mmPCa are associated with better overall survival, highlighting the importance of grading and staging in treatment outcomes.
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
BJU Int
August 2024
St. Vincent's Prostate Cancer Research Centre, Sydney, New South Wales, Australia.
Objectives: To prospectively compare systemic anti-tumour immune responses induced by irreversible electroporation (IRE) and robot-assisted radical prostatectomy (RARP) in patients with localised intermediate-risk prostate cancer (PCa).
Patients And Methods: Between February 2021 and June 2022, before and after treatment (at 5, 14 and 30 days) peripheral blood samples of 30 patients with localised PCa were prospectively collected. Patient inclusion criteria were: International Society of Urological Pathologists Grade 2-3, clinical cancer stage ≤T2c, prostate-specific antigen level <20 ng/mL).
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer.
Diagnostics (Basel)
June 2024
Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
Unlabelled: Oligometastatic patients at [F]F-Fluorocholine (F-choline) PET/CT may be treated with metastasis-directed therapy (MDT). The aim of this study was to combine radiomic parameters extracted from F-choline PET/CT and clinical data to build machine learning (ML) models able to predict MDT efficacy.
Methods: Oligorecurrent patients (≤5 lesions) at F-choline PET/CT and treated with MDT were collected.
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
Int J Cancer
October 2024
Icon Cancer Centre, Richmond, Victoria, Australia.
Metastasis-directed therapy (MDT) for oligometastatic prostate cancer (PCa), including stereotactic body radiotherapy (SBRT), has shown promise but is still considered investigational. This is the 5-year analysis of the TRANSFORM trial, the largest prospective cohort of men with oligometastatic PCa treated with SBRT-based MDT. The primary endpoint was 5-year treatment escalation-free survival (TE-FS), defined as freedom from any new cancer therapy other than further SBRT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!